CLINICAL TRIAL SUMMARY

MDACC Study No:RTOG0724 (clinicaltrials.gov NCT No: NCT00980954)
Title:PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY
Principal Investigator:Ann Klopp
Treatment Agent:Carboplatin; Cisplatin; Paclitaxel; Radiation
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the addition of
carboplatin and paclitaxel to cisplatin and radiation can help to control
cervical cancer better than cisplatin and radiation alone.

Hide details for General InformationGeneral Information

Disease Group:Cervix
Phase of Study:Phase III
Treatment Agents:Carboplatin
Cisplatin
Paclitaxel
Radiation
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Outpatient Basis
Supported By:RTOG Data Monitoring Committee
RTOG
Return Visit:Standard for all cervical cancer patients treated at MDACC - every 3 months for
the 1st 2 years, and than every 6 months for the next 3 years once a year.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ann Klopp
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-6830
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults